Kinase packing defects as drug targets

被引:14
作者
Crespo, Alejandro [1 ]
Fernandez, Ariel
机构
[1] Rice Univ, Dept Bioengn, Houston, TX 77005 USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[3] Univ Chicago, Dept Comp Sci, Chicago, IL 60637 USA
关键词
D O I
10.1016/j.drudis.2007.09.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Protein kinases constitute major targets in molecular cancer therapy. The structural conservation of kinases causes specificity problems in most drug inhibitors, often resulting in dangerous side effects. Here we survey recent approaches in drug design that exploit a molecular marker for specificity: the pattern of packing defects. These packing defects are solvent-exposed intramolecular hydrogen bonds that may be protected by drugs upon association. In this light, we review design strategies to achieve paralogue discrimination, to control cross reactivity and to overcome drug resistance induced by target mutations.
引用
收藏
页码:917 / 923
页数:7
相关论文
共 47 条
[1]  
Attoub S, 2002, CANCER RES, V62, P4879
[2]   Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors [J].
Barnett, SF ;
Defeo-Jones, D ;
Fu, S ;
Hancock, PJ ;
Haskell, KM ;
Jones, RE ;
Kahana, JA ;
Kral, AM ;
Leander, K ;
Lee, LL ;
Malinowski, J ;
McAvoy, EM ;
Nahas, DD ;
Robinson, RG ;
Huber, HE .
BIOCHEMICAL JOURNAL, 2005, 385 :399-408
[3]   A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding [J].
Bogoyevitch, Marie A. ;
Fairlie, David P. .
DRUG DISCOVERY TODAY, 2007, 12 (15-16) :622-633
[4]   Molecular basis for specificity in the druggable kinome: sequence-based analysis [J].
Chen, Jianping ;
Zhang, Xi ;
Fernandez, Ariel .
BIOINFORMATICS, 2007, 23 (05) :563-572
[5]   Issues and progress with protein kinase inhibitors for cancer treatment [J].
Dancey, J ;
Sausville, EA .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (04) :296-313
[6]   Macromollecullar recognition [J].
Deremble, C ;
Lavery, R .
CURRENT OPINION IN STRUCTURAL BIOLOGY, 2005, 15 (02) :171-175
[7]  
Donato NJ, 2000, CLIN CANCER RES, V6, P2965
[8]   Molecularly targeted Therapy: Have the floodgates opened? [J].
Druker, BJ .
ONCOLOGIST, 2004, 9 (04) :357-360
[9]   Circumventing resistance to kinase-inhibitor therapy [J].
Druker, Brian J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2594-2596
[10]   A small molecule-kinase interaction map for clinical kinase inhibitors [J].
Fabian, MA ;
Biggs, WH ;
Treiber, DK ;
Atteridge, CE ;
Azimioara, MD ;
Benedetti, MG ;
Carter, TA ;
Ciceri, P ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Galvin, M ;
Gerlach, JL ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Insko, MA ;
Lai, AG ;
Lélias, JM ;
Mehta, SA ;
Milanov, ZV ;
Velasco, AM ;
Wodicka, LM ;
Patel, HK ;
Zarrinkar, PP ;
Lockhart, DJ .
NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336